V I S I T
WORLD’S CLINICAL LABORATORY NEWS LEADER ISSN 1068-1760
Vol. 35 No.2 • 4/2018
DAILY CLINICAL LAB NEWS
®
I
N
T
E
R
N
A
New Biomarkers Predict Outcome Of Cancer Immunotherapy elanoma and lung cancer can be combatted effectively through immunotherapy, which makes targeted use of the immune system’s normal function of regularly examining the body’s tissue for pathogens and damages. Specific inhibitors are used to activate immune cells in a way that makes them identify cancer cells as foreign bodies and eliminate them. This way, the immune system can boost its often weak immune response to allow it to even detect and destroy metastatic cancer cells.
M
T
I
O
N
t is known that activated immune cells of patients with viral hepatitis destroy hepatocyte, but its regulatory mechanism has not yet been described. Regulatory T cells (Tregs) inhibit activation of other immune cells and thus are important for homeostasis of the immune system. However, recent studies contradictorily show that immune inhibitory functions of regulatory T cells weaken in inflammatory conditions and the cells secrete inflammatory cytokines in response. Meanwhile, such a phenomenon was not observed in viral hepatitis including types A, B and C.
I
Cont’d on page 3
Noninvasive Test Detects Bladder Cancer
Liquid Biopsy Test Detects Eight Types of Common Cancers
n Europe, bladder cancer represents the fourth most common cancer in men and the 15th most common cancer in women, with 151,000 people diagnosed with the condition in 2012. In order to make a bladder cancer diagnosis, experts currently recommend cystoscopy for all patients with hematuria, in conjunction with computed tomography (CT) urography (in selected high-risk patients) or renal and bladder ultrasound. At the moment, cystoscopy cannot be replaced by cytology or
I
ased on an assessment of levels of circulating proteins and mutations in cell-free DNA, the newly-developed CancerSEEK assay can detect eight common cancer types that account for more than 60% of cancer deaths, five of which currently have no screening alternative.
Image: Courtesy of University of Alberta
B
See article on page 7
I
S
I
T
LINKXPRESS COM R E A D E R
S E R V I C E
®
P O R T A L
Renew /Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information:
Cont’d on page 4
new test allows simultaneous processing of any combination of four separate sexually transmitted infections: Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV) and Mycoplasma genitalium (MG), from one patient sample.
A
Cont’d on page 4
Experts Recommend Fewer Tests for Hospitalized Patients
®
code(s) of interest on 3 Mark LinkXpress inquiry matrix ®
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
INSIDE
Test Allows Simultaneous Processing of Four STDs
Identify LinkXpress codes of 1 interest as you read magazine on LinkXpress.com 2 Click to reach reader service portal
L
Cellular Mechanism Identified For Severe Viral Hepatitis
Cont’d on page 7
V
A
outine daily laboratory testing of hospitalized patients reflects a wasteful clinical practice that threatens the value of health care. Initiatives from numerous professional societies have identified repetitive laboratory testing in the face of clinical stability as low value care. Excessive phlebotomy can lead to hospital-acquired anemia, increased costs, and unnecessary downstream testing and procedures. Efforts to reduce the frequency of laboratory orders can improve patient satisfaction and reduce cost without negatively affecting patient outcomes.
Clinical News . . . . 2-28 IFCC News . . . . . . . . 29 Product News . . . 6-28 Industry News . . . . .33 Events Calendar . . . 34 PUBLISHED IN COOPERATION WITH
R
Cont’d on page 6
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<